Corpus overview


Overview

MeSH Disease

Human Phenotype

Transmission

Seroprevalence

antibody (1)

    displaying 1 - 2 records in total 2
    records per page




    Impact of hematologic malignancy MESHD and type of cancer MESHD therapy on COVID-19 severity and mortality: lessons from a large population-based registry study

    Authors: Julio García-Suárez*; Javier de la Cruz*; Ángel Cedillo; Pilar Llamas; Rafael Duarte; Víctor Jiménez-Yuste; José Ángel Hernández-Rivas; Rodrigo Gil-Manso; Mi Kwon; Pedro Sánchez-Godoy; Pilar Martínez-Barranco; Blanca Colás-Lahuerta; Pilar Herrera; Laurentino Benito-Parra; Adrián Alegre; Alberto Velasco; Arturo Matilla; María Concepción Aláez-Usón; Rafael Martos-Martínez; Carmen Martínez-Chamorro; Keina Susana-Quiroz; Juan Francisco Del Campo; Adolfo de la Fuente; Regina Herráez; Adriana Pascual; Elvira Gómez; Jaime Pérez-Oteyza; Elena Ruiz; Arancha Alonso; José González-Medina; Lucía Núñez Martín-Buitrago; Miguel Canales; Isabel González-Gascón; María Carmen Vicente-Ayuso; Susana Valenciano; María García Roa; Pablo Estival Monteliu; Javier López-Jiménez; Cristián Escolano Escobar; Javier Ortiz-Martín; José Luis Diez-Martin†; Joaquín Martínez-López†

    doi:10.21203/rs.3.rs-69133/v1 Date: 2020-08-31 Source: ResearchSquare

    Background Patients with cancer MESHD have been shown to have a higher risk of clinical severity and mortality compared to non-cancer MESHD patients with COVID-19. Patients with hematologic malignancies MESHD typically are known to have higher levels of immunosuppression and may develop more severe respiratory viral infections MESHD than patients with solid tumours MESHD. Data on COVID-19 in patients with hematologic malignancies MESHD are limited. Here we characterise disease severity and mortality, and evaluate potential prognostic factors for mortality.Methods In this population-based registry study, we collected de-identified data on clinical characteristics, treatment and outcomes in adult TRANS patients with hematologic malignancies MESHD and confirmed severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection MESHD within the Madrid region of Spain. Our case series included all patients admitted to 22 regional health service hospitals and 5 private healthcare centres between February 28 and May 25, 2020. The primary study outcome was all-cause mortality. We assessed the association between mortality and potential prognostic factors using Cox regression analyses adjusted for age TRANS, sex, comorbidities, hematologic malignancy MESHD and recent active cancer MESHD therapy.Results Of 833 patients reported, 697 were included in the analyses. Median age TRANS was 72 years (IQR 60–79), 413 (60%) patients were male TRANS, and 479 (69%) and 218 (31%) had lymphoid MESHD and myeloid malignancies, respectively. Clinical severity of COVID-19 was severe/critical in 429 (62%) patients. At data cutoff, 230 (33%) patients had died. Age TRANS ≥60 years (hazard ratios 3·17–10·1 vs <50 years), >2 comorbidities (1·41 vs ≤2), acute myeloid leukemia HP acute myeloid leukemia MESHD (2·22 vs non-Hodgkin lymphoma HP lymphoma MESHD) and active antineoplastic treatment with monoclonal antibodies SERO (2·02) or conventional chemotherapy (1·50 vs no active therapy) were associated with increased mortality. Conversely, Ph-negative myeloproliferative neoplasms MESHD neoplasms HP (0·33) and active treatment with hypomethylating agents (0·47) were associated with lower mortality. Overall, 574 (82%) patients received antiviral therapy. Mortality with severe/critical COVID-19 was higher with no therapy vs any antiviral combination therapy (2.20).Conclusions In this series of patients with hematologic malignancies MESHD and COVID-19, mortality was associated with higher age TRANS, more comorbidities, type of hematological malignancy MESHD and type of antineoplastic therapy. Further studies and long-term follow-up are required to validate these criteria for risk-stratification.

    Association of Cancer with Risk and Mortality of COVID-19: Results from the UK Biobank

    Authors: Zhuqing Shi; W. Kyle Resurreccion; Chi-Hsiung Wang; Jun Wei; Rong Na; S. Lilly Zheng; Liana K. Billings; Brian T. Helfand; Janardan Khandekar; Jianfeng Xu

    doi:10.1101/2020.07.10.20151076 Date: 2020-07-11 Source: medRxiv

    Although cancer MESHD has been associated with COVID-19 risk and mortality in hospital-based studies, few population-based studies have been reported. Utilizing data from the UK Biobank (UKB), a population-based prospective cohort, we formally tested the association of over 44 different types of cancer MESHD with COVID-19 infection MESHD and mortality among 7,661 subjects who were tested by June 17, 2020. Compared to non-cancer subjects, cancer MESHD subjects (N=1,521) had significantly lower overall risk for COVID-19 infection MESHD [odds ratio (OR) and 95% confidence interval (CI): 0.79 (0.68-0.92), P=2.60E-03]. However, a trend of higher risk for COVID-19 mortality was found among 256 COVID-19 positive cancer MESHD patients, especially for hematologic cancers MESHD such as non-Hodgkin lymphoma HP lymphoma MESHD [3.82 (1.17-12.01), P=0.02]. In cancer MESHD patients, while few demographic, lifestyle, genetic and comorbidity factors predicted risk for COVID-19 infection MESHD, older age TRANS, male TRANS sex, heart disease MESHD and hypertension HP hypertension MESHD significantly predicted COVID-19 mortality. The lower risk for COVID-19 infection MESHD is likely due to extra caution in COVID-19 prevention and more testing among cancer MESHD patients, an encouraging finding that demonstrates the feasibility of intervention. These results, if confirmed in future releases of UKB data and other independent populations, may provide guidance for COVID-19 prevention and treatment among cancer MESHD patients.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.